Phenotypes Associated with This Genotype

Genotype
MGI:4438895

• Allelic Composition: Smtn^tm2Gve/Smtn^tm2Gve
• Genetic Background: B6.129-Smtn^tm2Gve

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

abnormal heart weight ( J:158046 )

• increased heart weight to body weight ratio at 8 months of age

cardiac hypertrophy ( J:158046 )

• both the left and right ventricular walls are enlarged by morphometric analysis and expression analysis shows upregulation of hypertrophy markers

increased heart left ventricle weight ( J:158046 )

thick ventricular wall ( J:158046 )

• increase in the cross sectional area of both the left and right ventricular walls

abnormal systemic arterial blood pressure ( J:158046 )

• mean arterial pressure responses to intravenous bolus injections of phenylephrine are reduced

increased mean systemic arterial blood pressure ( J:158046 )

abnormal blood vessel physiology ( J:158046 )

• almost 2-fold greater distension of the aorta during the cardiac cycle by magnetic resonance imaging

decreased vasoconstriction ( J:158046 )

• the maximal contractions produced by the saphenous arteries are strongly and significantly decreased in response to K+ , the thromboxane A2 mimetic U46619, or the alpha1 1 adrenergic agonist, phenylephrine

• contractility of the femoral artery in response to K+ and phenylephrine is reduced

muscle

decreased vasoconstriction ( J:158046 )

• the maximal contractions produced by the saphenous arteries are strongly and significantly decreased in response to K+ , the thromboxane A2 mimetic U46619, or the alpha1 1 adrenergic agonist, phenylephrine

• contractility of the femoral artery in response to K+ and phenylephrine is reduced

growth/size/body

cardiac hypertrophy ( J:158046 )

• both the left and right ventricular walls are enlarged by morphometric analysis and expression analysis shows upregulation of hypertrophy markers